Biogen (BIIB) Holder Bedell Frazier Investment Counseling Has Decreased Holding by $8.75 Million as Market Valuation Declined; Van Berkom & Associates Trimmed Charles Riv Labs Intl (CRL) Holding as Valuation Rose

January 14, 2018 - By Linda Rogers

Bedell Frazier Investment Counseling Llc decreased its stake in Biogen Inc (BIIB) by 52.25% based on its latest 2017Q3 regulatory filing with the SEC. Bedell Frazier Investment Counseling Llc sold 27,960 shares as the company’s stock declined 13.45% while stock markets rallied. The institutional investor held 25,554 shares of the biological products (no diagnostic substances) company at the end of 2017Q3, valued at $8.00 million, down from 53,514 at the end of the previous reported quarter. Bedell Frazier Investment Counseling Llc who had been investing in Biogen Inc for a number of months, seems to be less bullish one the $71.05 billion market cap company. The stock increased 0.86% or $2.88 during the last trading session, reaching $335.95. About 885,516 shares traded. Biogen Inc. (NASDAQ:BIIB) has risen 4.94% since January 14, 2017 and is uptrending. It has underperformed by 11.76% the S&P500.

Van Berkom & Associates Inc decreased its stake in Charles Riv Labs Intl Inc (CRL) by 15.11% based on its latest 2017Q3 regulatory filing with the SEC. Van Berkom & Associates Inc sold 116,060 shares as the company’s stock rose 1.24% with the market. The institutional investor held 651,853 shares of the health care company at the end of 2017Q3, valued at $70.41M, down from 767,913 at the end of the previous reported quarter. Van Berkom & Associates Inc who had been investing in Charles Riv Labs Intl Inc for a number of months, seems to be less bullish one the $4.99 billion market cap company. The stock decreased 2.52% or $2.72 during the last trading session, reaching $105.34. About 694,058 shares traded or 81.70% up from the average. Charles River Laboratories International, Inc. (NYSE:CRL) has risen 7.06% since January 14, 2017 and is uptrending. It has underperformed by 9.64% the S&P500.

Investors sentiment increased to 1.13 in Q3 2017. Its up 0.25, from 0.88 in 2017Q2. It is positive, as 59 investors sold BIIB shares while 283 reduced holdings. 96 funds opened positions while 292 raised stakes. 181.16 million shares or 0.28% more from 180.66 million shares in 2017Q2 were reported. Moreover, New Mexico Educational Retirement Board has 0.3% invested in Biogen Inc. (NASDAQ:BIIB) for 19,874 shares. Peddock Cap Advsr Ltd holds 2,374 shares or 0.38% of its portfolio. Capital Inv Advsr Ltd Limited Liability Company has invested 0.03% in Biogen Inc. (NASDAQ:BIIB). Toronto Dominion Financial Bank holds 80,414 shares. Virtu Finance Llc accumulated 3,684 shares. Ontario Teachers Pension Plan Board invested in 0.03% or 6,407 shares. Teachers Retirement Of The State Of Kentucky holds 0.22% in Biogen Inc. (NASDAQ:BIIB) or 59,340 shares. Victory Capital Mngmt Inc holds 0.01% in Biogen Inc. (NASDAQ:BIIB) or 8,433 shares. Lenox Wealth Mngmt Inc invested in 29 shares. Glg Ltd Company holds 0.73% or 36,128 shares in its portfolio. Shufro Rose & Com Ltd Llc invested in 1,500 shares or 0.05% of the stock. Atlantic Grp Ltd Liability Corporation owns 16,692 shares or 0.02% of their US portfolio. Baldwin Brothers Inc Ma owns 400 shares. Invesco Limited holds 0.39% or 3.38M shares. Rosenbaum Jay D owns 2,104 shares.

Bedell Frazier Investment Counseling Llc, which manages about $216.92 million US Long portfolio, upped its stake in Whirlpool Corp (NYSE:WHR) by 17,015 shares to 65,198 shares, valued at $12.03M in 2017Q3, according to the filing.

Since January 9, 2018, it had 0 buys, and 1 insider sale for $1.92 million activity.

Analysts await Biogen Inc. (NASDAQ:BIIB) to report earnings on January, 25. They expect $5.52 EPS, up 9.52% or $0.48 from last year’s $5.04 per share. BIIB’s profit will be $1.17 billion for 15.22 P/E if the $5.52 EPS becomes a reality. After $6.31 actual EPS reported by Biogen Inc. for the previous quarter, Wall Street now forecasts -12.52% negative EPS growth.

Among 31 analysts covering Biogen Idec Inc. (NASDAQ:BIIB), 22 have Buy rating, 0 Sell and 9 Hold. Therefore 71% are positive. Biogen Idec Inc. had 95 analyst reports since July 23, 2015 according to SRatingsIntel. Morgan Stanley maintained Biogen Inc. (NASDAQ:BIIB) rating on Wednesday, August 17. Morgan Stanley has “Overweight” rating and $368 target. The rating was initiated by Raymond James on Tuesday, September 1 with “Strong-Buy”. The firm has “Outperform” rating by Wells Fargo given on Friday, December 4. Citigroup downgraded Biogen Inc. (NASDAQ:BIIB) on Monday, October 23 to “Neutral” rating. The rating was maintained by RBC Capital Markets on Monday, July 27 with “Outperform”. The rating was upgraded by Goldman Sachs on Wednesday, July 26 to “Buy”. Morgan Stanley maintained the shares of BIIB in report on Wednesday, June 14 with “Hold” rating. The rating was maintained by RBC Capital Markets on Wednesday, October 25 with “Hold”. The firm earned “Buy” rating on Monday, July 27 by Argus Research. As per Friday, August 25, the company rating was maintained by Robert W. Baird.

Since August 14, 2017, it had 0 insider buys, and 6 sales for $4.64 million activity. Smith David Ross had sold 2,552 shares worth $171,228 on Monday, August 14. $382,229 worth of Charles River Laboratories International, Inc. (NYSE:CRL) was sold by FOSTER JAMES C on Tuesday, January 2. Another trade for 24,759 shares valued at $2.72M was made by JOHST DAVID P on Thursday, October 5. On Thursday, August 17 Barbo William D sold $399,632 worth of Charles River Laboratories International, Inc. (NYSE:CRL) or 4,000 shares.

Analysts await Charles River Laboratories International, Inc. (NYSE:CRL) to report earnings on February, 13. They expect $1.26 EPS, up 4.13% or $0.05 from last year’s $1.21 per share. CRL’s profit will be $59.67M for 20.90 P/E if the $1.26 EPS becomes a reality. After $1.30 actual EPS reported by Charles River Laboratories International, Inc. for the previous quarter, Wall Street now forecasts -3.08% negative EPS growth.

Among 16 analysts covering Charles River Laboratories (NYSE:CRL), 8 have Buy rating, 1 Sell and 7 Hold. Therefore 50% are positive. Charles River Laboratories had 39 analyst reports since August 3, 2015 according to SRatingsIntel. As per Wednesday, November 30, the company rating was upgraded by Barclays Capital. Jefferies maintained Charles River Laboratories International, Inc. (NYSE:CRL) on Friday, January 8 with “Buy” rating. The firm earned “Hold” rating on Thursday, October 12 by KeyBanc Capital Markets. The stock of Charles River Laboratories International, Inc. (NYSE:CRL) has “Buy” rating given on Monday, April 24 by Jefferies. The company was maintained on Thursday, August 31 by Robert W. Baird. The rating was upgraded by Evercore to “Buy” on Wednesday, January 4. The company was maintained on Thursday, November 16 by SunTrust. The firm earned “Hold” rating on Friday, July 31 by Deutsche Bank. The firm has “Buy” rating by Jefferies given on Thursday, June 29. As per Monday, November 13, the company rating was maintained by KeyBanc Capital Markets.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>